(19)
(11)EP 3 187 169 B1

(12)EUROPEAN PATENT SPECIFICATION

(45)Mention of the grant of the patent:
17.06.2020 Bulletin 2020/25

(21)Application number: 15835822.6

(22)Date of filing:  27.07.2015
(51)International Patent Classification (IPC): 
A61K 8/81(2006.01)
A61Q 11/00(2006.01)
C08F 230/02(2006.01)
A61K 8/34(2006.01)
A61K 8/55(2006.01)
A61P 1/02(2006.01)
(86)International application number:
PCT/JP2015/071197
(87)International publication number:
WO 2016/031461 (03.03.2016 Gazette  2016/09)

(54)

ORAL COMPOSITION FOR ALLEVIATION OF DENTIN HYPERSENSITIVITY

ORALE ZUSAMMENSETZUNG ZUR LINDERUNG VON DENTINÜBEREMPFINDLICHKEIT

COMPOSITION ORALE POUR LE SOULAGEMENT DE L'HYPERSENSIBILITÉ DE LA DENTINE


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 29.08.2014 JP 2014174782

(43)Date of publication of application:
05.07.2017 Bulletin 2017/27

(73)Proprietor: NOF Corporation
Shibuya-ku Tokyo 150-6019 (JP)

(72)Inventors:
  • MIYAMOTO Koji
    Kawasaki-shi Kanagawa 210-0865 (JP)
  • YAMAMOTO Nobuyuki
    Kawasaki-shi Kanagawa 210-0865 (JP)
  • SAKURAI Shunsuke
    Kawasaki-shi Kanagawa 210-0865 (JP)
  • SHIMAMURA Yoshihisa
    Kawasaki-shi Kanagawa 210-0865 (JP)

(74)Representative: Mewburn Ellis LLP 
Aurora Building Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB)


(56)References cited: : 
WO-A1-00/48561
JP-A- 2004 506 663
JP-A- 2006 273 767
JP-A- 2011 153 101
JP-B2- 3 889 449
WO-A2-02/15809
JP-A- 2006 273 767
JP-A- 2011 153 101
JP-A- 2013 545 801
  
      
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


    Description


    [0001] The present invention relates to an oral composition comprising a phosphorylcholine-containing polymer for use in a method of reducing dentinal hypersensitivity and a phosphorylcholine-containing polymer for use in a method of reducing dentinal hypersensitivity.

    [0002] A painful symptom of dentinal hypersensitivity is caused by a tissue fluid flow change in a dentinal tubule due to a physical stimulus of teeth grinding, brushing, or the like, a stimulus with cold water, etc. It is considered that this symptom is caused when an enamel for blocking the external stimulus is peeled off or a gum is lowered due to a periodontal disease or advancing age, whereby a dentin is exposed and the stimulus is transmitted directly to a dental pulp through the dentinal tubule.

    [0003] Therefore, in several known methods, the dentinal tubule is physically protected to prevent the transmission of the stimulus to the dental pulp. For example, a method containing forming a polymer membrane on the exposed dentin surface to reduce the dentinal hypersensitivity, a method containing forming a hard coating of an adhesive resin, and the like have been known. However, only qualified dentists can perform these methods. General consumers cannot utilize the methods routinely.

    [0004] In a known method that general consumers can utilize routinely, an oral composition containing aluminum lactate for protecting the dentinal tubule or potassium nitrate for reducing a sensitivity of a dental pulp cell is used to reduce the dentinal hypersensitivity.

    [0005] However, the aluminum lactate and potassium nitrate each have an inherent bitter, astringent, or harsh taste. Patent Literature 1 discloses a method for reducing the unpleasant taste.

    [0006] In addition, the potassium nitrate is disadvantageously less soluble in the case of using the potassium nitrate in combination with sodium lauryl sulfate. Patent Literature 2 discloses a technology for preventing precipitation of the potassium nitrate at low temperature.

    [0007] Furthermore, Patent Literature 3 discloses a phosphorylcholine-containing polymer usable in an oral composition, and Patent Literature 4 discloses a method using the phosphorylcholine-containing polymer in the oral composition to prevent microbial adhesion in an oral cavity.

    [0008] Patent Literature 5 discloses usefulness of the phosphorylcholine-containing polymer in dentistry. Specifically, Patent Literature 5 describes a technology for preventing adhesion of a microorganism such as a mold or fungus to a tooth surface.

    [0009] Patent Literature 6 discloses that the phosphorylcholine-containing polymer can be used in a hypersensitivity-reducing agent in the dental material field. Specifically, Patent Literature 6 discloses a dental composition containing the phosphorylcholine-containing polymer as a tooth surface coating agent.

    [0010] Patent Literature 7 discloses a composition for the treatment of sensitive teeth comprising a tubule blocking agent and a nerve desensitizing agent, wherein the tubule blocking agent deposits or swells upon the dentinal surface and/or precipitates within the dentinal tubules, retaining a higher concentration of the nerve desensitizing agent at the exposed dentinal surface and within the dentinal tubules.

    [0011] Patent Literature 8 discloses a desensitizing agent for the cleaning of sensitive teeth comprising repeating hydrophobic and hydrophilic regions.

    Patent Literature 1: WO 2011/055709

    Patent Literature 2: JP 2005-68071 A

    Patent Literature 3: JP 2006-273767 A

    Patent Literature 4: JP 2011-153101 A

    Patent Literature 5: JP 07-506138 T

    Patent Literature 6: JP 2007-217516 A

    Patent Literature 7: WO 02/15809 A2

    Patent Literature 8: WO 00/48561 A1



    [0012] The dentinal hypersensitivity-reducing methods disclosed in Patent Literatures 1 and 2 using the composition containing the potassium nitrate are disadvantageous in that the contents of the ingredients are limited as described above. The technology disclosed in Patent Literature 6 for coating a tooth surface with the phosphorylcholine-containing polymer to reduce the hypersensitivity should be performed by a dentist or the like.

    [0013] An object of the present invention is to provide an oral composition comprising a phosphorylcholine-containing polymer for use in a method of reducing dental hypersensitivity that a general consumer can use routinely.

    [0014] Another object of the present invention is to provide a phosphorylcholine-containing polymer for use in a method of reducing dentinal hypersensitivity.

    [0015] As a result of intense research in view of the above objects, the inventors have found that a general consumer per se can easily reduce dentinal hypersensitivity using a preparation containing a phosphorylcholine-containing polymer as an active ingredient. The present invention has been accomplished based on this finding.

    [0016] According to an aspect of the present invention, there is provided an oral composition comprising a phosphorylcholine-containing polymer for use in a method of reducing dentinal hypersensitivity.

    [0017] It is preferred that the phosphorylcholine-containing polymer comprises at least one polymer selected from the group consisting of homopolymers of 2-methacryloyloxyethyl phosphorylcholine (hereinafter may be referred to as MPC), copolymers of MPC and butyl methacrylate, copolymers of MPC and stearyl methacrylate, and copolymers of MPC and 2-hydroxy-3-methacryloyloxypropyl trimethyl ammonium chloride.

    [0018] In the present invention, the weight-average molecular weight (Mw) of the phosphorylcholine-containing polymer is preferably 10,000 to 10,000,000, more preferably 50,000 to 5,000,000.

    [0019] The oral composition for use according to the present invention preferably contains 0.001% to 10% by mass of the phosphorylcholine-containing polymer.

    [0020] The oral composition for use according to the present invention preferably has a pH of 5 to 11.

    [0021] It is preferred that the oral composition for use according to the present invention further contains at least one ingredient selected from the group consisting of glycerin, sorbitol, maltitol, and xylitol. It is further preferred that the oral composition contains 1% to 25% by mass of the ingredient.
    It is preferred that the method comprises bringing the oral composition into contact with an oral cavity of a user.

    [0022] According to another aspect of the present invention, there is provided a phosphorylcholine-containing polymer for use in a method of reducing dentinal hypersensitivity.

    [0023] The oral composition for use according to the present invention contains the phosphorylcholine-containing polymer as an active ingredient. A general consumer can use the oral composition in daily life, and can reduce the dentinal hypersensitivity easily and effectively.

    [0024] Particularly in a case where the oral composition contains at least one ingredient selected from the group consisting of glycerin, sorbitol, maltitol, and xylitol, the oral composition can exhibit an enhanced moisturizing effect in an oral cavity in addition to the effect of reducing the dentinal hypersensitivity.

    Fig. 1 is an electron micrograph of a dentin surface of a bovine tooth section with a dentinal tubule exposed therefrom.

    Fig. 2 is an electron micrograph of the dentin surface of the bovine tooth section taken after a dentinal hypersensitivity-reducing oral composition of Example 7-1 is brought into contact with the surface.

    Fig. 3 is an electron micrograph of the dentin surface of the bovine tooth section taken after an aqueous PEG solution of Comparative Example 7-1 is brought into contact with the surface.



    [0025] The present invention will be described in more detail below.

    [0026] The oral composition for use according to the present invention contains a phosphorylcholine-containing polymer as an active ingredient. The oral composition for use according to the present invention may contain only the phosphorylcholine-containing polymer, and preferably further contains a water. In the case of using the water, the phosphorylcholine-containing polymer is dissolved or dispersed in the water. It is preferred from the viewpoint of safety that the water is a purified water, a pure water, an ion-exchanged water, or the like.

    [0027] Preferred examples of the phosphorylcholine-containing polymers include homopolymers of a phosphorylcholine-containing monomer and copolymers of the phosphorylcholine-containing monomer and a (meth)acrylic acid derivative monomer. The phosphorylcholine-containing monomer is preferably 2-methacryloyloxyethyl phosphorylcholine (MPC).

    [0028] Specific examples of such phosphorylcholine-containing polymers include homopolymers of MPC, copolymers of MPC and methyl acrylate, copolymers of MPC and ethyl (meth)acrylate, copolymers of MPC and butyl (meth)acrylate, copolymers of MPC and lauryl acrylate, copolymers of MPC and stearyl (meth)acrylate, copolymers of MPC and 2-ethylhexyl acrylate, copolymers of MPC and benzyl (meth)acrylate, copolymers of MPC and phenoxyethyl (meth)acrylate, copolymers of MPC and cyclohexyl (meth)acrylate, copolymers of MPC and polypropylene glycol mono(meth)acrylate, copolymers of MPC and polytetramethylene glycol mono(meth)acrylate, copolymers of MPC and polypropylene glycol di(meth)acrylate, copolymers of MPC and polytetramethylene glycol mono(meth)acrylate, copolymers of MPC and polypropylene glycol/polyethylene glycol mono(meth)acrylate, and copolymers of MPC and 2-hydroxy-3-methacryloyloxypropyl trimethyl ammonium chloride. Particularly preferred among them are homopolymers of 2-methacryloyloxyethyl phosphorylcholine, copolymers of 2-methacryloyloxyethyl phosphorylcholine and butyl methacrylate, copolymers of 2-methacryloyloxyethyl phosphorylcholine and stearyl methacrylate, and copolymers of 2-methacryloyloxyethyl phosphorylcholine and 2-hydroxy-3-methacryloyloxypropyl trimethyl ammonium chloride.

    [0029] More specifically, homopolymers of MPC prepared by a polymerization method according to JP 10-298240 A, copolymers of MPC and butyl methacrylate prepared by a polymerization method according to JP 11-035605 A, copolymers of MPC and butyl methacrylate prepared by a polymerization method according to JP 2004-196868 A, copolymers of MPC and stearyl methacrylate prepared by a polymerization method according to JP 2004-196868 A, and copolymers of MPC and 2-hydroxy-3-methacryloyloxypropyl trimethyl ammonium chloride prepared by a polymerization method according to JP 2004-189678 A can be used as the phosphorylcholine-containing polymer in the present invention.

    [0030] In a case where the phosphorylcholine-containing polymer is the copolymer of the phosphorylcholine-containing monomer and the (meth)acrylic acid derivative monomer, the copolymerization ratio of the phosphorylcholine-containing monomer is preferably 30% by mole or more. The upper limit of the copolymerization ratio is not particularly restricted. When the copolymerization ratio is within this range, the phosphorylcholine-containing polymer exhibits an excellent dentinal hypersensitivity-reducing action.

    [0031] The phosphorylcholine-containing polymer, which is used as an active ingredient in the present invention, preferably has a weight-average molecular weight of 10,000 to 10,000,000. The weight-average molecular weight is more preferably 50,000 to 5,000,000 in view of a mixing process in production of the phosphorylcholine-containing polymer. When the weight-average molecular weight is too low, the phosphorylcholine-containing polymer does not exhibit an effect appropriate for the amount of the polymer. When the weight-average molecular weight is too high, the phosphorylcholine-containing polymer exhibits a flavoring effect, but may cause a bad use feeling. For example, a coating of the polymer may have an excessively strong presence in an oral cavity.

    [0032] The oral composition for use according to the present invention may contain an ingredient other than the above described water. Specifically, the oral composition may be an oral care product such as a dentifrice, a mouthwash, a mouth freshener, or an oral rinse.

    [0033] The oral composition may be prepared in a form of a liquid, a viscous liquid, a gel, an emulsion, a solid such as a tablet, or the like, without particular restrictions.

    [0034] In the oral composition for use according to the present invention, the concentration of the phosphorylcholine-containing polymer is preferably 0.001% to 10% by mass. When the concentration is within this range, the oral composition exhibits a good dentinal hypersensitivity-reducing effect. When the concentration is more than 10% by mass, the oral composition has an excessively high viscosity and thus may exhibit a poor handling property in use.

    [0035] The oral composition for use according to the present invention preferably has a pH of 5 to 11. When the composition is not a solid, the pH is that of the oral composition per se. When the composition is a solid, the pH is that of a solution or dispersion containing 10% by mass of the composition in water.

    [0036] The oral composition for use according to the present invention may contain another ingredient. Examples of the other ingredients include buffers, wetters, antiphlogistics, hemostats, hypersensitivity-reducing agents, tooth decay-preventing agents, tartar deposition-preventing agents, mouth deodorants, astringents, dental plaque removers, vitamin supplements, washing aids, surfactants, antiseptic disinfectants, sweeteners, thickeners, solvents, colorants, organic acids, inorganic salts,
    antioxidants, stabilizers, preservatives, sequestrants, fragrances, flavoring agents, fresheners, and dyes.

    [0037] Examples of the buffers include, but not limited thereto, citric acid, phosphoric acid, malic acid, gluconic acid, and salts thereof. The content of the buffer is preferably 0.01% to 3% by mass based on the entire oral composition in view of controlling the pH of the oral composition at 5 to 11.

    [0038] Examples of the wetters include polyols such as glycerin, propylene glycol, butylene glycol, pentylene glycol, dipropylene glycol, polyethylene glycol, xylitol, sorbitol, mannitol, maltitol, and erythritol. In a case where the oral composition contains at least one ingredient selected from the group consisting of glycerin, sorbitol, maltitol, and xylitol, the oral composition can exhibit an improved moisturizing effect in the oral cavity without decrease of the dentinal hypersensitivity-reducing effect. The content of the wetter is preferably 1% to 25% by mass based on the entire oral composition.

    [0039] Examples of the antiphlogistics include, but not limited thereto, sodium azulene sulfonate, allantoin, aluminum chlorohydroxyallantoinate, aluminum hydroxyallantoinate, epi-dihydroxycholesterol, dihydrocholesterol, glycyrrhizic acid and salts thereof, β-glycyrrhetinic acid, lysozyme chloride, and methyl salicylate.

    [0040] Examples of the hemostats include, but not limited thereto, epsilon-aminocaproic acid and tranexamic acid.

    [0041] Examples of the hypersensitivity-reducing agents include, but not limited thereto, potassium nitrate and aluminum lactate.

    [0042] Examples of the tooth decay-preventing agents include, but not limited thereto, sodium fluoride and sodium monofluorophosphate.

    [0043] Examples of the tartar deposition-preventing agents include, but not limited thereto, disodium dihydrogen pyrophosphate, sodium pyrophosphate, and zinc chloride.

    [0044] Examples of the mouth deodorants include, but not limited thereto, sodium copper chlorophyllin.

    [0045] Examples of the astringents include, but not limited thereto, sodium chloride and 1-menthol.

    [0046] Examples of the dental plaque removers include, but not limited thereto, polyethylene glycols and polyvinylpyrrolidones.

    [0047] Examples of the vitamin supplements include, but not limited thereto, ascorbic acid and salts thereof, pyridoxine hydrochloride, dl-α-tocopherol acetate, and dl-α-tocopherol nicotinate.

    [0048] Examples of the washing aids include, but not limited thereto, zeolites, sodium monohydrogen phosphate, trisodium phosphate, and sodium polyphosphate.

    [0049] Examples of the surfactants include, but not limited thereto, polyoxyethylene lauryl ethers (8 to 10 E.O.), sodium lauroyl sarcosinate, polyoxyethylene hydrogenated castor oils, polyoxyethylene sorbitan fatty acid esters, polyglycerin fatty acid esters, acylamino acid salts, fatty acid amide propyl betaines, and fatty acid amide betaines. It is particularly preferred that the oral composition contains 0.05% to 2% by mass of a polyoxyethylene hydrogenated castor oil or a polyoxyethylene sorbitan fatty acid ester.

    [0050] Examples of the antiseptic disinfectants include, but not limited thereto, isopropylmethylphenol, cetylpyridinium chloride, dequalinium chloride, benzalkonium chloride, benzethonium chloride, alkyldiaminoethylglycine hydrochlorides, chlorhexidine hydrochloride, chlorhexidine gluconate, triclosan, 1,8-cineole, polyhexanide hydrochloride, hinokitiol, benzoic acid and salts thereof, and paraben-based substances.

    [0051] Examples of the sweeteners include, but not limited thereto, saccharin, stevioside, sucrose, aspartame, and licorice extracts.

    [0052] Examples of the thickeners include, but not limited thereto, cellulose-based thickeners such as methylcelluloses, hydroxyethylcelluloses, hydroxypropylcelluloses, hydroxypropylmethylcelluloses, and carboxymethylcelluloses, and polysaccharides such as hyaluronic acids and salts thereof, chondroitin sulfates and salts thereof, alginic acids and salts thereof, gellan gums, and xanthane gums.

    [0053] Examples of the solvents include, but not limited thereto, ethanol and the like, in addition to the above-described waters.

    [0054] The solvent, colorant, organic acid, inorganic salt, antioxidant, stabilizer, preservative, sequestrant, fragrance, flavoring agent, freshener, and dye may be selected from conventional ones for oral compositions.

    [0055] The present invention preferably comprises bringing the oral composition for use according to the present invention into contact with an oral cavity of a user. For example, the oral composition may be brought into contact with the oral cavity of the user by rinsing the user's mouth with the oral composition, by brushing the user's teeth using the oral composition as the dentifrice, by spraying the oral composition onto the oral cavity, or by gargling with the oral composition.

    [0056] The present invention and the advantageous effects will be described more specifically below with reference to Examples and Comparative Examples without intention of restricting the invention.

    1. Evaluation of improvement of pain caused by dentinal hypersensitivity



    [0057] Dentinal hypersensitivity-reducing oral compositions of Examples and compositions of Comparative Examples were each evaluated with respect to prevention or reduction of dentinal hypersensitivity pain immediately after use and 2 hours after use.

    [0058] Triers for conducting the evaluation were persons who suffered dental hypersensitivity pain every day or 2 to 3 times a week over the last one month.

    [0059] In the evaluation, each of three triers used the composition, and put cold water (4°C) in mouth to evaluate the dentinal hypersensitivity pain immediately after and 2 hours after the use. The dentinal hypersensitivity pain was rated on a scale of 1 to 3, with 3 indicating that the trier felt no pain, 2 indicating that the trier felt slight pain, and 1 indicating that the trier felt pain. The average value of the rating values was considered as the dentinal hypersensitivity pain evaluation result of the composition. A larger average value means that the dentinal hypersensitivity pain is prevented or reduced more effectively by the composition.

    2. Evaluation of moisture retention in oral cavity



    [0060] Dentinal hypersensitivity-reducing oral compositions of Examples and compositions of Comparative Examples were each evaluated with respect to moisture retention in oral cavity before and after use.

    [0061] Triers for conducting the evaluation were persons who suffered dental hypersensitivity pain every day or 2 to 3 times a week over the last one month.

    [0062] In the evaluation, each of three triers used the composition, and the moisture retention in the oral cavity was measured before and after the use by the oral moisture checker MUCUS (trademark) available from K. K. Life. In each trier, the moisture retention measured before the use was defined as a reference value of 100, and the moisture retention measured after the use was converted to a value relative to the reference value.

    Examples 1-1 to 1-12



    [0063] Dentinal hypersensitivity-reducing oral compositions shown in Table 1 were prepared in the following manner.

    [0064] In Examples 1-1 to 1-6 and 1-8 to 1-12, a phosphorylcholine-containing polymer was added to a purified water, stirred at the room temperature for 10 minutes, and thereby dissolved in the purified water to prepare a dentinal hypersensitivity-reducing oral composition in the form of an aqueous solution. The pH of the oral composition was measured.

    [0065] In Example 1-7, a copolymer of MPC and stearyl methacrylate was added little by little to a purified water at 80°C and subjected to an ultrasonic treatment to prepare a dispersion. The dispersion was cooled to the room temperature to prepare a dentinal hypersensitivity-reducing oral composition in the form of an aqueous dispersion. The pH of the oral composition was measured.

    [0066] The dentinal hypersensitivity-reducing oral composition of each Example was used as a mouthwash, and was evaluated with respect to the dentinal hypersensitivity pain improvement and the moisture retention in oral cavity as described above. The results are shown in Table 1.

    Comparative Examples 1-1 to 1-4



    [0067] In Comparative Examples 1-1 to 1-4, a soybean lecithin was added little by little to a purified water at 80°C, and subjected to an ultrasonic treatment to prepare a dispersion. The dispersion was cooled to the room temperature to prepare a composition shown in Table 2. The pH of the composition was measured.

    [0068] The composition of each Comparative Example was used in the same manner as above-described Examples, and was evaluated with respect to the dentinal hypersensitivity pain improvement and the moisture retention in oral cavity as described above. The results are shown in Table 2.

    Table 2
     Comp. Ex. 1-1Comp. Ex. 1-2Comp. Ex. 1-3Comp. Ex. 1-4
    Ingredient Soybean lecithin 0.10 1.00 5.00 10.00
    Purified water 99.90 99.00 95.00 90.00
    Total 100.00 100.00 100.00 100.00
    pH 5.0 5.0 5.0 5.0
    Evaluation of pain Immediately after use 1.0 1.0 1.0 1.1
    2 hours after use 1.0 1.0 1.0 1.0
    Evaluation of moisture retention in oral cavity 2 hours after use 100 100 99 99

    Examples 2-1 to 2-8



    [0069] Oral compositions shown in Table 3 were prepared in the following manner.

    [0070] Ingredients other than phosphorylcholine-containing polymers were added in arbitrary order to a purified water, mixed at the room temperature for 10 minutes, and thereby dissolved in the purified water. After confirmation of the dissolving, a phosphorylcholine-containing polymer was added thereto, mixed at the room temperature for 10 minutes, and thereby dissolved in the solution, to prepare an oral composition. The pH of the oral composition was measured.

    [0071] The oral composition of each Example was used as a mouthwash, and was evaluated with respect to the dentinal hypersensitivity pain improvement and the moisture retention in oral cavity as described above. The results are shown in Table 3.

    Comparative Examples 2-1 to 2-4



    [0072] In Comparative Examples 2-1 to 2-4, a soybean lecithin was added little by little to a purified water at 80°C, and subjected to an ultrasonic treatment to prepare a dispersion. The dispersion was cooled to the room temperature. Then, sodium hydrogen phosphate and sodium dihydrogen phosphate were added thereto successively, glycerin was further added in Comparative Example 2-4, and the resultant was mixed for 5 minutes, so that the ingredients were dissolved in the purified water, to prepare each composition shown in Table 4. The pH of the composition was measured.

    [0073] The composition of each Comparative Example was used in the same manner as above-described Examples, and was evaluated with respect to the dentinal hypersensitivity pain improvement and the moisture retention in oral cavity as described above. The results are shown in Table 4.



    Table 4
     Comp. Ex. 2-1Comp. Ex. 2-2Comp. Ex. 2-3Comp. Ex. 2-4
    Ingredient Soybean lecithin 0.10 1.00 5.00 5.00
    Sodium hydrogen phosphate 0.20 0.20 0.20 0.20
    Sodium dihydrogen phosphate 0.40 0.40 0.40 0.40
    Glycerin       8.00
    Purified water 99.30 98.40 94.40 86.40
    Total 100.00 100.00 100.00 100.00
    pH 6.5 6.5 6.5 6.5
    Evaluation of pain Immediately after use 1.0 1.0 1.0 1.1
    2 hours after use 1.0 1.0 1.0 1.0
    Evaluation of moisture retention in oral cavity 2 hours after use 100 99 98 101

    Example 3-1



    [0074] An oral composition shown in Table 5 was prepared as a dentifrice in the following manner.

    [0075] In a vacuum mixer, ingredients of addition order A were added to a purified water at the room temperature, dispersed for 5 minutes, and heated to 80°C and dissolved in the purified water. Ingredients of addition order B were added thereto and mixed. After confirmation of dissolution, ingredients of addition order C were added thereto and dissolved therein. The resultant was mixed for 30 minutes, cooled, and degassed under reduced pressure, to prepare an oral composition as a dentifrice. The pH of the oral composition was measured.

    [0076] The oral composition was used as a dentifrice, and was evaluated with respect to the dentinal hypersensitivity pain improvement and the moisture retention in oral cavity as described above. The results are shown in Table 5.

    Examples 3-2 to 3-12



    [0077] Oral compositions were prepared as dentifrices in the same manner as Example 3-1 except that the types and amounts of the ingredients were changed as shown in Table 5. The pH of each oral composition was measured.

    [0078] The oral composition of each Example was used as a dentifrice, and was evaluated with respect to the dentinal hypersensitivity pain improvement and the moisture retention in oral cavity as described above. The results are shown in Table 5.




    Examples 4-1 to 4-7



    [0079] Oral compositions shown in Table 6 were prepared as mouthwashes in the following manner.

    [0080] A purified water was heated to 80°C, and ingredients shown in Table 6 were dissolved in the purified water in amounts shown in Table 6, to prepare an oral composition as a mouthwash. Incidentally, in the case of using a lemon oil as a fragrance, the lemon oil was preliminarily mixed with a polyoxyethylene hydrogenated castor oil or a polysorbate 80, and then added to the purified water at 80°C. The pH of each mouthwash of the oral composition was measured.

    [0081] The oral composition of each Example was used as a mouthwash, and was evaluated with respect to the dentinal hypersensitivity pain improvement and the moisture retention in oral cavity as described above. The results are shown in Table 6.
    Table 6
     Ex. 4-1Ex. 4-2Ex. 4-3Ex. 4-4Ex. 4-5Ex. 4-6Ex. 4-7
      MPC homopolymer (Mw 100,000) 0.50            
      MPC/butyl methacrylate copolymer 1 (Mw 600,000   0.50       0.50 0.50
      MPC/butyl methacrylate copolymer 2 (Mw 100,000     0.50     0.50  
      MPC/stearyl methacrylate copolymer (Mw 250,000)       0.05      
      MPC/2-hydroxy-3-methacryloyloxypropyl trimethyl ammonium chloride copolymer (Mw 450,000)         1.00   0.50
      Sodium dihydrogen phosphate 0.10 0.10          
    Ingredient Sodium citrate     0.20 0.20 0.20 0.20 0.20
      Glycerin 10.00 8.00          
      Sorbitol     15.00 15.00 15.00 10.00 8.00
      Xylitol 5.00   3.00        
      Maltitol   2.00   3.00 3.00 3.00 3.00
      Cetylpyridinium chloride     0.05 0.05 0.01    
      Benzethonium chloride 0.01 0.01       0.01 0.01
      Polyoxyethylene hydrogenated castor oil   2.00          
      Polysorbate 80     1.00   0.50 0.50 0.50
      Dipotassium glycyrrhizinate     0.05 0.10 0.10    
      Fragrance (lemon oil)   0.05 0.05        
      Ethyl p-hydroxybenzoate 0.01 0.01 0.01 0.01 0.01 0.01 0.01
      Ethanol 15.00   15.00        
      Purified water 69.38 87.33 65.14 81.59 80.18 85.28 87.28
    Total 100.00 100.00 100.00 100.00 100.00 100.00 100.00
    pH 6.8 6.8 6.8 6.8 6.8 6.8 6.8
    Evaluation of pain Immediately after use 2.7 2.7 2.7 2.4 2.5 2.5 2.5
    2 hours after use 2.4 2.4 2.5 2.2 2.3 2.3 2.3
    Evaluation of moisture retention in oral cavity 2 hours after use 106 112 112 105 111 111 109
    MPC/butyl methacrylate copolymer 1: copolymerization ratio 8:2 (mole ratio)
    MPC/butyl methacrylate copolymer 2: copolymerization ratio 3:7 (mole ratio)

    Examples 5-1 to 5-5



    [0082] Oral compositions shown in Table 7 were prepared as mouth fresheners in the following manner.

    [0083] Ingredients of addition order B were dissolved in ethanol at the room temperature to prepare an ethanol solution. Separately, ingredients of addition order A were dissolved in a purified water at the room temperature to prepare an aqueous solution. The aqueous solution was added to the ethanol solution, and mixed and dissolved for 10 minutes to prepare each oral composition as a mouth freshener. The pH of each oral composition was measured.

    [0084] The oral composition of each Example was sprayed as a mouth freshener onto an oral cavity, and was evaluated with respect to the dentinal hypersensitivity pain improvement and the moisture retention in oral cavity as described above. The results are shown in Table 7.
    Table 7
     OrderEx. 5-1Ex. 5-2Ex. 5-3Ex. 5-4Ex. 5-5
    Ingredient MPC homopolymer (Mw 100,000) A 1.00        
    MPC/butyl methacrylate copolymer 1 (Mw 600,000   1.00      
    MPC/butyl methacrylate copolymer 2 (Mw 100,000     1.00    
    MPC/stearyl methacrylate copolymer (Mw 250,000)       1.00  
    MPC/2-hydroxy-3-methacryloyloxypropyl trimethyl ammonium chloride copolymer (Mw 450,000         1.00
    Glycerin 10.00 10.00      
    Sorbitol     12.00 12.00 12.00
    Xylitol 5.00   5.00    
    Maltitol   5.00   3.00 3.00
    I-Menthol B 0.50 0.50 0.50 0.50 0.50
    Polyoxyethylene hydrogenated castor oil 0.50 1.00 1.00 1.00  
    Lemon oil 0.01 0.05 0.05    
    Ethanol 40.00 40.00 40.00 40.00 40.00
    Purified water A 42.99 42.45 40.45 42.50 43.50
    Total   100.00 100.00 100.00 100.00 100.00
    pH 5.1 5.2 5.1 5.1 5.1
    Evaluation of pain Immediately after use 2.8 2.8 2.8 2.8 2.5
    2 hours after use 2.3 2.4 2.4 2.5 2.2
    Evaluation of moisture retention in oral cavity 2 hours after use 108 111 109 110 105
    MPC/butyl methacrylate copolymer 1: copolymerization ratio 8:2 (mole ratio)
    MPC/butyl methacrylate copolymer 2: copolymerization ratio 3:7 (mole ratio)

    Examples 6-1 to 6-5



    [0085] Oral compositions shown in Table 8 were prepared as oral rinses in the following manner.

    [0086] Ingredients of addition order A were dissolved in a purified water at the room temperature to prepare an aqueous solution. Separately, ingredients of addition order B were dissolved in ethanol at the room temperature to prepare an ethanol solution. The ethanol solution was added to the aqueous solution, and mixed and dissolved for 10 minutes to prepare each oral composition as an oral rinse. The pH of each oral composition was measured.

    [0087] The oral composition of each Example was used as an oral rinse, and was evaluated with respect to the dentinal hypersensitivity pain improvement and the moisture retention in oral cavity as described above. Incidentally, each oral composition shown in Table 8 was 50-fold diluted in the use of the oral rinse. The results are shown in Table 8.
    Table 8
     OrderEx. 6-1Ex. 6-2Ex. 6-3Ex. 6-4Ex. 6-5
      MPC homopolymer (Mw 100,000) A 1.00        
      MPC/butyl methacrylate copolymer 1 (Mw 600,000)   1.00      
      MPC/butyl methacrylate copolymer 2 (Mw 100,000)     1.00    
      MPC/stearyl methacrylate copolymer (Mw 250,000)       0.30  
      MPC/2-hydroxy-3-methacryloyloxypropyl trimethyl ammonium Chloride copolymer (Mw 450,000)         1.00
    Ingredient Sodium citrate 0.10 0.10 0.10 0.10 0.10
      Glycerin 15.00 8.00      
      Sorbitol     15.00 15.00 15.00
      Xylitol 5.00 1.00 3.00    
      Maltitol   1.00   3.00 3.00
      Povidone iodine 6.80     6.80 6.80
      Cetylpyridinium chloride   0.25 0.25    
      Dipotassium glycyrrhizinate   0.25      
      I-Menthol B 0.75 0.75 0.75 0.25  
      Polyoxyethylene hydrogenated castor oil 1.00 1.00   1.00  
      Saccharine sodium 0.60 0.60 0.60 0.60 0.60
      Ethanol 30.00 30.00 30.00 27.95 27.95
      Purified water A 39.75 56.05 49.30 45.00 45.55
    Total   100.00 100.00 100.00 100.00 100.00
    pH 6.8 6.8 6.8 6.8 6.8
    Evaluation of pain Immediately after use 2.7 2.7 2.6 2.5 2.6
    2 hours after use 2.7 2.6 2.4 2.3 2.4
    Evaluation retention in of moisture oral cavity 2 hours after use 112 110 106 110 105
    MPC/butyl methacrylate copolymer 1: copolymerization ratio 8:2 (mole ratio)
    MPC/butyl methacrylate copolymer 2: copolymerization ratio 3:7 (mole ratio)


    [0088] The polymers shown in the tables will be described in more detail below.

    [0089] MPC homopolymer: A homopolymer of 2-methacryloyloxyethyl phosphorylcholine, having a weight-average molecular weight of 100,000, prepared by a polymerization method described in Examples of JP 10-298240 A.

    [0090] MPC/butyl methacrylate copolymer 1: A copolymer of 2-methacryloyloxyethyl phosphorylcholine and butyl methacrylate, having a copolymerization ratio (by mole) of 80/20 and a weight-average molecular weight of 600,000, prepared by a polymerization method described in Examples of JP 11-035605 A.

    [0091] MPC/butyl methacrylate copolymer 2: A copolymer of 2-methacryloyloxyethyl phosphorylcholine and butyl methacrylate, having a copolymerization ratio (by mole) of 30/70 and a weight-average molecular weight of 100,000, prepared by a polymerization method described in Examples of JP 2004-196868 A.

    [0092] MPC/stearyl methacrylate copolymer: A copolymer of 2-methacryloyloxyethyl phosphorylcholine and stearyl methacrylate, having a copolymerization ratio (by mole) of 33/67 and a weight-average molecular weight of 250,000, prepared by a polymerization method described in Examples of JP 2004-196868 A.

    [0093] MPC/2-hydroxy-3-methacryloyloxypropyl trimethyl ammonium chloride copolymer: A copolymer of 2-methacryloyloxyethyl phosphorylcholine and 2-hydroxy-3-methacryloyloxypropyl trimethyl chloride ammonium, having a copolymerization ratio (by mole) of 70/30 and a weight-average molecular weight of 450,000, prepared by a polymerization method described in Examples of JP 2004-189678 A.

    [0094] With regard to the evaluation of the dentinal hypersensitivity pain improvement, the average values rated by the triers were 2 or more in Examples 1-1 to 1-12, whereas the average values were 1 in Comparative Examples 1-1 to 1-4. Thus, in Examples 1-1 to 1-12, the dentinal hypersensitivity was significantly reduced. It is clear from the results that the phosphorylcholine-containing polymer is useful as an active ingredient for reducing the dentinal hypersensitivity.

    [0095] Furthermore, the average values rated by the triers were 2 or more in Examples 2-1 to 2-8, whereas the average values were 1 in Comparative Examples 2-1 to 2-4. Thus, also in Examples 2-1 to 2-8, the dentinal hypersensitivity was significantly reduced.

    [0096] With regard to the evaluation of the moisture retention in oral cavity, the values measured after the use remained approximately the same as the values measured before the use in Comparative Examples 2-1 to 2-4. In contrast, in Examples 2-1 to 2-8, the moisture retentions in oral cavity were higher after the use than before the use, so that the oral compositions exhibited excellent moisturizing effects.

    3. Evaluation of protection of dentinal tubule in bovine tooth


    Example 7-1



    [0097] The MPC/butyl methacrylate copolymer 1 (Mw 600,000) was dissolved in a purified water to prepare a dentinal hypersensitivity-reducing oral composition having a concentration of 5% by mass. The oral composition was brought into contact with a bovine tooth with exposed dentinal tubules, and the degree of protection for the dentinal tubules was observed by an electronic microscope.

    [0098] Specifically, the test was carried out in the following manner. A bovine tooth was taken and cut vertically to the tooth axis using the precision cutter ISOMET (available from Buehler ITW Japan) to prepare bovine tooth sections having a thickness of 1.5 mm. Then, a step of keeping the bovine tooth section in contact with a 50% aqueous citric acid solution for 3 minutes was repeated twice to remove the smear layer. The bovine tooth section was washed with a purified water, and the dentin surface of the section was dried by air blow. The prepared dentinal hypersensitivity-reducing oral composition was left in contact with the bovine tooth section for 30 seconds. Furthermore, the bovine tooth section was left in contact with a 2.5% aqueous glutaraldehyde phosphate buffer for 30 minutes. Finally, the bovine tooth section was sufficiently dried and observed using a scanning electron microscope SU1510 (available from Hitachi High-Technologies Corporation).

    [0099] An electron micrograph of the untreated bovine tooth with the exposed dentinal tubules is shown in Fig. 1, and an electron micrograph of the bovine tooth taken after the contact with the dentinal hypersensitivity-reducing oral composition is shown in Fig. 2.

    Comparative Example 7-1



    [0100] An aqueous solution containing a polyethylene glycol (PEG, Mw 100,000) at a concentration of 5% by mass was used instead of the dentinal hypersensitivity-reducing oral composition of Example 7-1. This aqueous PEG solution was brought into contact with the bovine tooth having the exposed dentinal tubules in the same manner as Example 7-1.

    [0101] An electron micrograph of the bovine tooth taken after the contact with the aqueous PEG solution is shown in Fig. 3.

    [0102] As is clear from Figs. 1 to 3, the dentinal hypersensitivity-reducing oral composition of Example 7-1 acted to protect the dentinal tubules significantly, whereas the PEG of Comparative Example 7-1 exhibited no effect of protecting the dentinal tubules.


    Claims

    1. An oral composition comprising a phosphorylcholine-containing polymer for use in a method of reducing dentinal hypersensitivity.
     
    2. The oral composition for use according to claim 1, wherein the phosphorylcholine-containing polymer comprises at least one polymer selected from the group consisting of homopolymers of 2-methacryloyloxyethyl phosphorylcholine, copolymers of 2-methacryloyloxyethyl phosphorylcholine and butyl methacrylate, copolymers of 2-methacryloyloxyethyl phosphorylcholine and stearyl methacrylate, and copolymers of 2-methacryloyloxyethyl phosphorylcholine and 2-hydroxy-3-methacryloyloxypropyl trimethyl ammonium chloride, and has a weight-average molecular weight of 10,000 to 10,000,000.
     
    3. The oral composition for use according to claim 1 or 2, comprising 0.001% to 10% by mass of the phosphorylcholine-containing polymer.
     
    4. The oral composition for use according to any one of claims 1 to 3, having a pH of 5 to 11.
     
    5. The oral composition for use according to any one of claims 1 to 4, further comprising at least one ingredient selected from the group consisting of glycerin, sorbitol, maltitol, and xylitol.
     
    6. The oral composition for use according to any one of claims 1 to 5, wherein the method comprises bringing the oral composition in to contact with an oral cavity of a user.
     
    7. A phosphorylcholine-containing polymer for use in a method of reducing dentinal hypersensitivity.
     
    8. The phosphorylcholine-containing polymer for use according to claim 7, wherein the method comprises bringing the phosphorylcholine-containing polymer into contact with an oral cavity of a user.
     
    9. The phosphorylcholine-containing polymer for use according to claim 7 or 8, wherein phosphorylcholine-containing polymer comprises at least one polymer selected from the group consisting of homopolymers of 2-methacryloyloxyethyl phosphorylcholine, copolymers of 2-methacryloyloxyethyl phosphorylcholine and butyl methacrylate, copolymers of 2-methacryloyloxyethyl phosphorylcholine and stearyl methacrylate, and copolymers of 2-methacryloyloxyethyl phosphorylcholine and 2-hydroxy-3-methacryloyloxypropyl trimethyl ammonium chloride, and has a weight-average molecular weight of 10,000 to 10,000,000.
     


    Ansprüche

    1. Orale Zusammensetzung, umfassend ein Phosphorylcholin enthaltendes Polymer zur Verwendung in einem Verfahren zur Verringerung von Dentinüberempfindlichkeit.
     
    2. Orale Zusammensetzung zur Verwendung nach Anspruch 1, wobei das Phosphorylcholin enthaltende Polymer mindestens ein Polymer, ausgewählt aus der Gruppe, bestehend aus Homopolymeren von 2-Methacryloyloxyethylphosphorylcholin, Copolymeren von 2-Methacryloyloxyethylphosphorylcholin und Butylmethacrylat, Copolymeren von 2-Methacryloyloxyethylphosphorylcholin und Stearylmethacrylat und Copolymeren von 2-Methacryloyloxyethylphosphorylcholin und 2-Hydroxy-3-methacryloyloxypropyltrimethylammoniumchlorid, umfasst, und ein gewichtsmittleres Molekulargewicht von 10.000 bis 10.000.000 aufweist.
     
    3. Orale Zusammensetzung zur Verwendung nach Anspruch 1 oder 2, umfassend 0,001 Massen-% bis 10 Massen-% des Phosphorylcholin enthaltenden Polymers.
     
    4. Orale Zusammensetzung zur Verwendung nach einem der Ansprüche 1 bis 3 mit einem pH von 5 bis 11.
     
    5. Orale Zusammensetzung zur Verwendung nach einem der Ansprüche 1 bis 4, ferner umfassend mindestens einen Bestandteil, ausgewählt aus der Gruppe, bestehend aus Glycerin, Sorbit, Maltit und Xylit.
     
    6. Orale Zusammensetzung zur Verwendung nach einem der Ansprüche 1 bis 5, wobei das Verfahren umfasst, dass die orale Zusammensetzung mit einer Mundhöhle eines Benutzers in Kontakt gebracht wird.
     
    7. Phosphorylcholin enthaltendes Polymer zur Verwendung in einem Verfahren zur Verringerung von Dentinüberempfindlichkeit.
     
    8. Phosphorylcholin enthaltendes Polymer zur Verwendung nach Anspruch 7, wobei das Verfahren umfasst, dass das Phosphorylcholin enthaltende Polymer mit einer Mundhöhle eines Benutzers in Kontakt gebracht wird.
     
    9. Phosphorylcholin enthaltendes Polymer zur Verwendung nach Anspruch 7 oder 8, wobei das Phosphorylcholin enthaltende Polymer mindestens ein Polymer, ausgewählt aus der Gruppe, bestehend aus Homopolymeren von 2-Methacryloyloxyethylphosphorylcholin, Copolymeren von 2-Methacryloyloxyethylphosphorylcholin und Butylmethacrylat, Copolymeren von 2-Methacryloyloxyethylphosphorylcholin und Stearylmethacrylat und Copolymeren von 2-Methacryloyloxyethylphosphorylcholin und 2-Hydroxy-3-methacryloyloxypropyltrimethylammoniumchlorid, umfasst, und ein gewichtsmittleres Molekulargewicht von 10.000 bis 10.000.000 aufweist.
     


    Revendications

    1. Composition orale comprenant un polymère contenant de la phosphorylcholine pour une utilisation dans un procédé de réduction d'hypersensibilité dentinaire.
     
    2. Composition orale pour une utilisation selon la revendication 1, dans laquelle le polymère contenant de la phosphorylcholine comprend au moins un polymère choisi dans le groupe consistant en homopolymères de 2-méthacryloyloxyéthylphosphorylcholine, copolymères de 2-méthacryloyloxyéthylphosphorylcholine et méthacrylate de butyle, copolymères de 2-méthacryloyloxyéthylphosphorylcholine et méthacrylate de stéaryle, et copolymères de 2-méthacryloyloxyéthylphosphorylcholine et chlorure de 2-hydroxy-3-méthacryloyloxypropyltriméthylammonium, et présente une masse moléculaire moyenne en masse de 10 000 à 10 000 000.
     
    3. Composition orale pour une utilisation selon la revendication 1 ou 2, comprenant de 0,001 % à 10 % en masse du polymère contenant de la phosphorylcholine.
     
    4. Composition orale pour une utilisation selon l'une quelconque des revendications 1 à 3, présentant un pH de 5 à 11.
     
    5. Composition orale pour une utilisation selon l'une quelconque des revendications 1 à 4, comprenant de plus au moins un ingrédient choisi dans le groupe consistant en glycérine, sorbitol, maltitol, et xylitol.
     
    6. Composition orale pour une utilisation selon l'une quelconque des revendications 1 à 5, dans laquelle le procédé comprend la mise en contact de la composition orale avec une cavité orale d'un utilisateur.
     
    7. Polymère contenant de la phosphorylcholine pour une utilisation dans un procédé de réduction d'hypersensibilité dentinaire.
     
    8. Polymère contenant de la phosphorylcholine pour une utilisation selon la revendication 7, dans lequel le procédé comprend la mise en contact du polymère contenant de la phosphorylcholine avec une cavité orale d'un utilisateur.
     
    9. Polymère contenant de la phosphorylcholine pour une utilisation selon la revendication 7 ou 8, dans lequel le polymère contenant de la phosphorylcholine comprend au moins un polymère choisi dans le groupe consistant en homopolymères de 2-méthacryloyloxyéthylphosphorylcholine, copolymères de 2-méthacryloyloxyéthylphosphorylcholine et méthacrylate de butyle, copolymère de 2-méthacryloyloxyéthylphosphorylcholine et méthacrylate de stéaryle, et copolymères de 2-méthacryloyloxyéthylphosphorylcholine et chlorure de 2-hydroxy-3-méthacryloyloxypropyltriméthylammonium, et présente une masse moléculaire moyenne en masse de 10 000 à 10 000 000.
     




    Drawing











    Cited references

    REFERENCES CITED IN THE DESCRIPTION



    This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

    Patent documents cited in the description